Table 3. Risk of Epiphora, Cystoid Macular Edema, and Optic Neuropathy Among Women With Breast Cancer Taking Tamoxifen or Taxane Chemotherapy.
| Characteristic | HR (95% CI) | |
|---|---|---|
| Crudea | Adjusted | |
| Epiphora | ||
| Tamoxifen | 1 [Reference] | 1 [Reference] |
| Docetaxel/paclitaxel | 6.60 (3.30-13.21) | 6.42 (3.13-13.15) |
| Cystoid macular edema | ||
| Tamoxifen | 1 [Reference] | 1 [Reference] |
| Docetaxel/paclitaxel | 1.45 (0.60-3.48) | 1.37 (0.57-3.31) |
| Optic neuropathy | ||
| Tamoxifen | 1 [Reference] | 1 [Reference] |
| Docetaxel/paclitaxel | 11.18 (1.34-93.35) | 10.73 (1.07-107.63) |
Abbreviation: HR, hazard ratio.
a
Hazard ratios were adjusted for aromatase inhibitors (anastrozole, exemestane, and letrozole), keratoconjunctivitis, dry eye syndrome, keratitis, blepharitis, eyelid malposition, cataracts, diabetes, and coronary artery disease.